Jean Jacques Bienaime - Jun 3, 2024 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 3, 2024
Transactions value $
$0
Form type
4
Date filed
6/5/2024, 04:11 PM
Previous filing
Jun 5, 2024
Next filing
Jun 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (right to buy) Award $0 +17.6K $0.00 17.6K Jun 3, 2024 Common Stock 17.6K $48.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on September 3, 2024, subject to the Reporting Person continuing to provide service through each such date.